HSBC's Downgrade of Eli Lilly#
HSBC has recently downgraded Eli Lilly's stock rating to "Reduce." The bank's analyst, Rajesh Kumar, argues that the market's expectations for the rapidly growing obesity drug sector have become overly optimistic. According to HSBC, Eli Lilly's shares now appear to be "priced to perfection," meaning they are valued at a level that may not be sustainable given current market conditions.
Price Target Reduction#
As part of this downgrade, HSBC has lowered its price target for Eli Lilly from $1,070 to $850. This adjustment reflects concerns about the company's future performance in a competitive healthcare environment. While HSBC believes the broader healthcare sector may perform well in the upcoming quarter, they caution that high valuations and crowded market positions pose significant risks.
Concerns About Market Expectations#
HSBC's downgrade is based on three main concerns. Firstly, the bank believes that the total addressable market (TAM) for obesity drugs is overestimated. While the market expects it to exceed $150 billion, HSBC's own estimate is between $80 billion and $120 billion by 2032. This discrepancy raises questions about the sustainability of growth in this sector.
Competition and Launch Expectations#
Secondly, HSBC anticipates increased price competition in the obesity drug market, particularly with upcoming price cuts expected in 2026. This could challenge the assumptions that Eli Lilly has built into its future guidance. Additionally, the bank warns that expectations surrounding the launch of Lilly's oral obesity drug may be too high, as the effectiveness and patient adherence to these medications could fall short of market forecasts.
Finally, HSBC points out a divergence between Eli Lilly's guidance and that of its competitor, Novo Nordisk. This difference highlights Lilly's heavy reliance on cash-paying customers, which may be more vulnerable to economic fluctuations and disruptions in the job market related to artificial intelligence.